Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Gynecol Oncol. 2019 Oct 22;155(3):483–488. doi: 10.1016/j.ygyno.2019.10.008

Table 4.

Multivariate analysis of IHC markers and correlation with patient and tumor factors

PD-1 TILS PD-L1 IHC PD-1 positive lymphocytes PD-L1 CPS
HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age (by 10 years) 1.29 0.91 – 1.83 0.154 1.26 0.91 – 1.75 0.168 1.21 0.857 – 1.70 0.2827 1.20 0.853 – 1.69 0.2964
Tumor site
 Ovary Referent Referent Referent Referent
 Uterine 1.52 0.32 – 7.25 0.603 2.01 0.43 – 9.35 0.3754 2.39 0.454 – 12.57 0.3041 2.48 0.484 – 12.70 0.2759
Stage
 I or II Referent Referent Referent Referent
 III 3.37 0.94 – 11.99 0.061 3.77 1.01 – 14.02 0.048 3.82 1.084 – 13.48 0.0371 3.99 1.096 – 14.53 0.0358
 IV 7.21 1.68 – 31.03 0.008 7.11 1.64 – 30.86 0.009 6.27 1.456 – 27.03 0.0137 6.23 1.444 – 26.89 0.0142

Abbreviations: TILS: tumor infiltrating lymphocytes; CPS: combined positive score; IHC: Immunohistochemistry